leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...116117118119120121122123124125126...235236»
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Clinical, Journal:  Partial response of donafenib as the third-line therapy in metastatic colon cancer: A case report. (Pubmed Central) -  Oct 29, 2021   
    SCRT-CH with non-operative intent for pts in locoregional cCR is a promising treatment paradigm for OM1 rectal cancer pts. This case report provides clinicians with a safe and effective option for donafenib as a later-line treatment option for patients with metastatic colorectal cancer to improve their overall survival and quality of life.
  • ||||||||||  oxaliplatin / Generic mfg., irinotecan / Generic mfg.
    Enrollment closed, Surgery:  Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (clinicaltrials.gov) -  Oct 28, 2021   
    P2,  N=46, Active, not recruiting, 
    This case report provides clinicians with a safe and effective option for donafenib as a later-line treatment option for patients with metastatic colorectal cancer to improve their overall survival and quality of life. Recruiting --> Active, not recruiting
  • ||||||||||  dexamethasone / Generic mfg., ceftriaxone / Generic mfg., ifosfamide / Generic mfg.
    [VIRTUAL] NASAL SUBTYPE T/NK CELL LYMPHOMA IN PEDIATRIC PATIENT: CASE REPORT () -  Oct 27, 2021 - Abstract #HEMO2021HEMO_1194;    
    Report A 12-year-old male patient started with a clinical picture of progressive and intense odynophagia, with an evolution of approximately 1 month, associated with the appearance of a painful ulcer in the transition region between the hard and soft palate on the right, and episodes of daily low fever. Biopsy of a lesion whose report was not conclusive was performed. The patient evolved with facial edema, most notably on the right and nasal obstruction, and empirical treatment for sinusitis was instituted with clindamycin and ceftriaxone. There was no response with treatment and progressed with partial respiratory obstruction during sleep. A CT scan of the facial sinuses showed an expansive and infiltrative lesion in the nasopharynx, measuring approximately 6.0×5.2×3.4 cm, associated with pansinusopathy. He underwent a new biopsy with histopathological report of lymphoproliferative disease. Immunophenotyping and immunohistochemistry of the specimen confirmed the diagnosis of extranodal NK/T lymphoma, nasal type. In staging it was classified as IIE. Treated with two chemotherapy cycles with m-SMILE protocol, without significant toxicity, with significant clinical and radiological improvement. Therapeutic proposal to be followed with radiotherapy and new imaging test to assess the need for a new cycle of chemotherapy. Discussion Nasal type NK/T cell lymphoma is rare, particularly in the pediatric population, with a higher incidence in East Asia and the indigenous population of America Latin. Nasal-type NK/T cell lymphoma is an aggressive extranodal subtype that presents with infiltration, necrosis, and angioinvasion. Its association with EBV is well known and when negative, the diagnosis should be questioned. EBV viral load is a possible biomarker for prognosis and therapeutic response, as it is related to tumor load. The patient in question had a negative test for EBV in the specimen by immunohistochemistry, however quantitative PCR for EBV in the blood was positive with 16.19 copies per 1 million cells. Treatment for localized diseases is mainly based on radiotherapy associated with chemotherapy. Natural killer cells express a high concentration of P-glycoprotein, which confers resistance to multiple drugs, including anthracyclines. Thus, the SMILE protocol (methotrexate, leucovorin, ifosfamide, dexamethasone, etoposide and pegasparaginase) has been chosen in recent years as the preferred chemotherapy regimen, with L-asparaginase playing an important role. The 5-year overall survival is approximately 40–50%. According to the prognostic index of natural killer lymphoma (Pink), in addition to the EBV viral load, they provide a worse prognosis: age over 60 years, stage III or IV, non-nasal type and distant lymph node involvement. In patients without risk factors, as in the case reported, the 3-year survival can reach 81%. That said, it is important that the follow-up of patients be prolonged, as there is a risk of late relapse. The role of bone marrow transplantation is uncertain, as studies carried out date back to when the treatment regimen was still based on anthracyclines. The overall 3-year survival for allogeneic and autologous transplant patients was 39–64%.
  • ||||||||||  Enrollment closed:  PROTECT: PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer (clinicaltrials.gov) -  Oct 27, 2021   
    P2,  N=106, Active, not recruiting, 
    Discussion Nasal type NK/T cell lymphoma is rare, particularly in the pediatric population, with a higher incidence in East Asia and the indigenous population of America Latin. Nasal-type NK/T cell lymphoma is an aggressive extranodal subtype that presents with infiltration, necrosis, and angioinvasion. Its association with EBV is well known and when negative, the diagnosis should be questioned. EBV viral load is a possible biomarker for prognosis and therapeutic response, as it is related to tumor load. The patient in question had a negative test for EBV in the specimen by immunohistochemistry, however quantitative PCR for EBV in the blood was positive with 16.19 copies per 1 million cells. Treatment for localized diseases is mainly based on radiotherapy associated with chemotherapy. Natural killer cells express a high concentration of P-glycoprotein, which confers resistance to multiple drugs, including anthracyclines. Thus, the SMILE protocol (methotrexate, leucovorin, ifosfamide, dexamethasone, etoposide and pegasparaginase) has been chosen in recent years as the preferred chemotherapy regimen, with L-asparaginase playing an important role. The 5-year overall survival is approximately 40–50%. According to the prognostic index of natural killer lymphoma (Pink), in addition to the EBV viral load, they provide a worse prognosis: age over 60 years, stage III or IV, non-nasal type and distant lymph node involvement. In patients without risk factors, as in the case reported, the 3-year survival can reach 81%. That said, it is important that the follow-up of patients be prolonged, as there is a risk of late relapse. The role of bone marrow transplantation is uncertain, as studies carried out date back to when the treatment regimen was still based on anthracyclines. The overall 3-year survival for allogeneic and autologous transplant patients was 39–64%. Recruiting --> Active, not recruiting
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  IMMUNOX: FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) -  Oct 27, 2021   
    P2,  N=0, Withdrawn, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 N=30 --> 0 | Trial completion date: Sep 2025 --> Sep 2021 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2025 --> Sep 2021
  • ||||||||||  Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
    Clinical, Journal:  A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer (Pubmed Central) -  Oct 22, 2021   
    Regorafenib, which has been approved as a salvage line for metastatic colorectal cancer, features many adverse events, and there are few cases in which the approved dose can be administered. In our case, starting at a low dose resulted in fewer adverse events, adequate disease control, and long-term administration.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal:  A Case of Advanced Gastric Cancer Successfully Treated with mFOLFOX6 Therapy (Pubmed Central) -  Oct 22, 2021   
    After 7 courses, the regimen was changed to 5-fluorouracil and Leucovorin(5-FU/l -LV)chemotherapy because of thrombocytopenia. For more than 10 months, he has continued to receive chemotherapy without the recurrence of metastasis.